News article view

Press releases

Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development

The companies will leverage their combined experience in the development of conjugate vaccines for their clients

  •  Primrose Bio will supply its industry-leading carrier protein, PeliCRM197®, for vaccine development
  • Intravacc has IP and know how in vaccine conjugation and manufacturing of carrier protein based products
  • Clients active in conjugate vaccines will benefit from a seamless solution across development and manufacturing

Bilthoven, The Netherlands, 26 march 2024 – Intravacc, a leading global contract development and manufacturing organization (CDMO) specializing in infectious disease and therapeutic vaccines, and Primrose Bio, a biotechnology company with leading technologies that improve the manufacturing of next-generation therapeutics, announced a strategic partnership to enhance the development and supply of conjugate vaccines. Third parties engaged in developing conjugate vaccines will have access to a seamless solution for vaccine conjugation, manufacturing and supply.

Dr. Jan Groen, Intravacc’s CEO, says: 

“We are excited to announce our partnership with Primrose Bio. By combining our expertise with Primrose's cutting-edge technologies, we aim to revolutionize the landscape of conjugate vaccine development, ultimately benefiting millions worldwide." 

Dr. Helge Zieler, Primrose Bio’s CEO, further comments:

“Expanding the capability of our PeliCRM197® franchise with Intravacc now creates a full-service solution for our early-stage customers and partners needing vaccine conjugation development. With both companies having direct product experience in preclinical, manufacturing, and clinical development, the combined know-how of the two firms fills a gap that is needed by the vaccine industry as a whole.”
This partnership harnesses the synergistic strengths of both companies, fostering innovation and efficiency in vaccine development. Intravacc contributes its comprehensive technical expertise, state-of-the-art facilities, and robust capabilities in antigen conjugation process development, scale-up, and GMP production of conjugate vaccines. Primrose Bio complements this with its ultra-pure production, supply chain, and regulatory support for the PeliCRM197® carrier protein, a vital ingredient in conjugate vaccine formulations and the only commercial CRM197 used in commercial vaccines available for purchase. This carrier protein is offered in a range of quantities and grades, from milligrams to kilograms, both for research and GMP applications. The partnership signifies a strategic alignment aimed at advancing vaccine development and accessibility for researchers and industry clients.

Download Press Release

Contact us

You can send us an email:

Reach out to Business Development:

Or pick up the phone: 
+31 30 792 03 00

You can also just fill out the contact form on the right.

We look forward to hearing from you!


Contact form

Subscribe to our newsletter